These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11775769)

  • 1. Biologic therapy for psoriasis: a brief history, II.
    Tutrone WD; Kagen MH; Barbagallo J; Weinberg JM
    Cutis; 2001 Dec; 68(6):367-72. PubMed ID: 11775769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
    Young MS; Horn EJ; Cather JC
    Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab.
    Strober BE
    Arch Dermatol; 2004 Mar; 140(3):366. PubMed ID: 15023789
    [No Abstract]   [Full Text] [Related]  

  • 4. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis.
    Babino G; Esposito M; Mazzotta A; Chimenti S; Giunta A
    Acta Derm Venereol; 2013 May; 93(3):373-4. PubMed ID: 23147755
    [No Abstract]   [Full Text] [Related]  

  • 6. Practical understanding of mean percent psoriasis area and severity index reduction for biologics.
    English PL; Vender R
    J Cutan Med Surg; 2008; 12(6):282-7. PubMed ID: 19317950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept.
    Krell JM
    J Am Acad Dermatol; 2006 Jun; 54(6):1099-101. PubMed ID: 16713481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Tutrone WD
    Cutis; 2003 Jan; 71(1):41-5. PubMed ID: 12553629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological therapy and nail psoriasis.
    Lawry M
    Dermatol Ther; 2007; 20(1):60-7. PubMed ID: 17403261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New biologic therapies for psoriatic disease.
    Bohjanen KA; Prawer SE
    Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
    Smith EC; Riddle C; Menter MA; Lebwohl M
    Int J Dermatol; 2008 May; 47(5):514-8. PubMed ID: 18412874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents.
    Ortiz A; Yamauchi PS
    Skinmed; 2006; 5(6):285-8. PubMed ID: 17085995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
    Langley RG; Ho V; Lynde C; Papp KA; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():18-25. PubMed ID: 16633860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety.
    Yamauchi PS; Gindi V; Lowe NJ
    Dermatol Clin; 2004 Oct; 22(4):449-59, ix. PubMed ID: 15450340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial watch: novel biologic for psoriasis shows superiority over current best-seller.
    Nat Rev Drug Discov; 2008 Nov; 7(11):880-1. PubMed ID: 18974743
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
    Saini R; Tutrone WD; Weinberg JM
    Curr Pharm Des; 2005; 11(2):273-80. PubMed ID: 15638763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series.
    Conley J; Nanton J; Dhawan S; Pearce DJ; Feldman SR
    J Dermatolog Treat; 2006; 17(2):86-9. PubMed ID: 16766332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.